Pfizer's JN.1 vaccine has been the only option available to Australians since the start of the year. Here's what happened to ...

As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new ...

Bank of America’s downgrade to ‘Underperform’ with a $7 target deepened concerns over Sanofi’s limited commercialization of ...

BofA forecasts slowing overall revenue, estimating about $1 billion in 2025, slightly below the company’s guidance. It ...

Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more ...

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is ...

If you want a COVID-19 shot this fall, will your employer’s health insurance plan pay for it? There’s no clear answer.

With so much in flux, it’s important to check with your employer or insurer about coverage policies before you roll up your ...

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Nuvaxovid product sales for 2025 are expected to be $610 million, and adjusted supply sales of $25-$40 million compared to prior expectation of $20 million- $35 million.

Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not have an impact on its operating profit for 2025. “Sanofi is picking up the ...